Case 2 : Management of Uncontrolled Hyperglycemia in a High Risk Diabetic Patient

Real World Case Series Issue 2

Clinical Case Brief

70 Year old Male

Social History :

  • Addicted to Tobacco and following sedentary Lifestyle

Family History :

  • Mother had T2DM

Physical Examination :

  • BP: 120/70 mmHg
  • Pulse: 104 beats/min
  • Height: 157 cm
  • Body Weight: 72.7 Kg

Laboratory Investigations before 13th Dec, 2023                                      

  • HbA1c: 7.3%
  • FBG: 242 mg/dl
  • PPG: 328 mg/dl
  • Creatinine: 1.52 mg/dl

Medical History :

  • T2DM from last 8 years
  • Hypothyroidism from last 14 years Also Diagnosed with following on 3rd  Nov’ 23
  • Dyslipidemia, Chronic Pancreatic Disease, Diabetic Kidney Disease
  • Heart Disease
  • Had undergone Cholecystectomy

Medication History :

  • Metformin- 1000 mg OD
  • Empagliflozin-25 mg OD
  • Glimepiride-4 mg OD
  • Thyroxine - 75 µg OD
  • Rosuvastatin- 10 mg OD
  • Etizolam-0.5 mg OD
  • Torsemide- 5mg OD
  • Silodosin + Dutasteride (8+0.5) mg OD

Patient Diagnosis: Uncontrolled Hyperglycemia

Expert's Concern :

  • Patient with Uncontrolled Hyperglycemia especially HbA1c and fasting plasma Glucose in the background of Chronic pancreatic disease

Revised Treatment on 13th Dec’ 2023 with Addition of Imeglimin: 1000 mg B.D.

Replaced Medication

  • Empagliflozin and Glimepiride

Post Follow up Changes in Medication :

  • Imeglimin: 1000 mg B.D
  • Metformin- 500 mg B.D
  • Gliclazide-60 mg BD
  • Pioglitazone- 15 mg BD

Key Findings after using Imeglimin

  • HbA1c: 8.6 %
  • FBG: 172 mg/dl
  • PPG: 71 mg/dl

Major Highlights of the Case    

Changes Done in Medication :

  • Replacement of Empagliflozin and Glimepiride with Addition of Imeglimin and Gliclazide Reduced the dose of Pioglitazone from 30mg to 15mg

Follow up Advice :

  • Imeglimin: 1000mg B.D continue for next 3 months

Experts’ View :

  • The Fasting Plasma Glucose at baseline 242 mg/dl is reduced to 172 mg/ dl
  • Post prandial plasma glucose at baseline 328 is reduced to 71 mg/dl in 2 months
  • The result of HbA1c will be followed after 3 months in periodic Check up

Benefits to patient :

  • No Adverse effect
  • No Hypoglycemia